Treatment with sublethal concentrations of SB633825 led to increased phosphorylation of eIF2α in a time-dependent manner (Figures 5H, I), with negligible effects on ATP release across multiple AML cell lines (Figure 5J). This evidence concerns the gene EIF2A and acute myeloid leukemia.